We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×

Treating neurodegenerative diseases with multitarget drugs: an interview with Maria João Matos

    Maria João Matos

    *Author for correspondence: Tel.: +34 881 815 047;

    E-mail Address: maria.matos@fc.up.pt

    ;

    E-mail Address: mariajoao.correiapinto@usc.es

    Centro de Investigação em Química da Universidade do Porto/Department of Chemistry & Biochemistry, University of Porto, Porto, 4169-007, Portugal

    Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain

    Published Online:https://doi.org/10.4155/fmc-2022-0077

    Neurodegenerative diseases are one of the leading causes of death, disability and dependency worldwide. Since the etiology of these complex pathologies is not completely known, the available therapeutic options can only cause temporary relief of the symptoms, but cannot cure them. Life-changing therapeutic solutions are urgently needed, as the number of people suffering from these pathologies has been increasing quickly over the last few decades. Recent studies regarding the paradigm of using multitarget compounds to treat both Alzheimer's and Parkinson's diseases have been analyzed and included in the review entitled “Multitarget therapeutic approaches for Alzheimer’s and Parkinson’s diseases: an opportunity or an illusion?”. This interview is based on this previously published overview, highlighting some of the most important aspects.

    Reference

    • 1. Matos MJ. Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion? Future Med. Chem. 13(15), 1301–1309 (2021).